FDA Votes in Favor of Benefit-Risk Profile for Moderna’s Flu Vaccine

Moderna said an advisory committee voted unanimously that the benefits of the vaccine, mRNA-1010, transcend the risks for the prevention of flu successful adults 50 done 64 years old, and successful adults 65 and older.